Cargando…

A randomized multicenter evaluation of the efficacy of 0.15% hyaluronic acid versus 0.05% cyclosporine A in dry eye syndrome

Hyaluronic acid (HA) and cyclosporine A (CsA) eyedrops are commonly prescribed in dry eye syndrome (DES). The effectiveness of each preparation in DES is well-known, yet the superiority of one over another has been studied little. We assessed the efficacy and tolerability of 0.15% HA compared to com...

Descripción completa

Detalles Bibliográficos
Autores principales:	Lee, Ji Eun, Kim, Sangyoon, Lee, Hyung Keun, Chung, Tae-Young, Kim, Jae Yong, Choi, Chul Young, Chung, So Hyang, Kim, Dong Hyun, Kim, Kyoung Woo, Chung, Jin Kwon, Hwang, Kyu Yeon, Hwang, Ho Sik, Kim, Jin Hyoung, Hyon, Joon Young
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Nature Publishing Group UK 2022
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9636392/ https://www.ncbi.nlm.nih.gov/pubmed/36333364 http://dx.doi.org/10.1038/s41598-022-21330-0

Ejemplares similares

A Randomized Multicenter Study Comparing 0.1%, 0.15%, and 0.3% Sodium Hyaluronate with 0.05% Cyclosporine in the Treatment of Dry Eye
por: Park, Yuli, et al.
Publicado: (2017)

Efficacy of Topical Cyclosporine Nanoemulsion 0.05% Compared with Topical Cyclosporine Emulsion 0.05% and Diquafosol 3% in Dry Eye
por: Park, Chang Hyun, et al.
Publicado: (2019)

The Effect of Topical Cyclosporine 0.05% on Dry Eye after Cataract Surgery
por: Chung, Yeon Woong, et al.
Publicado: (2013)

Comparison of 0.05% cyclosporine and 3% diquafosol solution for dry eye patients: a randomized, blinded, multicenter clinical trial
por: Park, Chang Hyun, et al.
Publicado: (2019)

A randomized controlled trial involving college student: Comparing 0.15% hyaluronic acid with 0.05% cyclosporine A and 3% diquafosol sodium in the Treatment of Dry Eye
por: Xu, Wenhao, et al.
Publicado: (2023)

Retraction Note: Comparison of 0.05% cyclosporine and 3% diquafosol solution for dry eye patients: a randomized, blinded, multicenter clinical trial
por: Park, Chang Hyun, et al.
Publicado: (2020)

Effectiveness and Optical Quality of Topical 3.0% Diquafosol versus 0.05% Cyclosporine A in Dry Eye Patients following Cataract Surgery
por: Lee, Jang Hoon, et al.
Publicado: (2016)

Comparative analysis of 0.1% cyclosporin A cationic emulsion and 0.05% cyclosporin A emulsion in murine dry eye cases with different severities
por: Jin, Rujun, et al.
Publicado: (2021)

Efficacy and safety of topical cyclosporine 0.1% in moderate-to-severe dry eye disease refractory to topical cyclosporine 0.05% regimen
por: Chan, Yuan-Hsi, et al.
Publicado: (2023)

Cyclosporine (0.05%) Combined with Diclofenac Sodium Eye Drops for the Treatment of Dry Eye Disease
por: Bai, Run, et al.
Publicado: (2022)

A Prospective Study of Cyclosporine A 0.1% Combined with Loteprednol 0.2% vs Cyclosporine A 0.05% Alone in the Treatment of Dry Eye
por: Hovanesian, John, et al.
Publicado: (2023)

The effect of topical 0.05% cyclosporine on recurrence following pterygium surgery
por: Turan-Vural, Ece, et al.
Publicado: (2011)

Patient and physician perspectives on the use of cyclosporine ophthalmic emulsion 0.05% for the management of chronic dry eye
por: Deveney, Tatiana, et al.
Publicado: (2018)

Cyclosporine 0.05% Ophthalmic Emulsion for Dry Eye in Korea: A Prospective, Multicenter, Open-Label, Surveillance Study
por: Byun, Yong-Soo, et al.
Publicado: (2011)

The Effect of Topical 0.05% Cyclosporine in the Prevention of Recurrence Following Pterygium Surgery
por: Karadag, Ayse Sevgi, et al.
Publicado: (2021)

Silkworm Protein-Derived Nitrogen-Doped Carbon-Coated Li[Ni(0.8)Co(0.15)Al(0.05)]O(2) for Lithium-Ion Batteries
por: Sim, Gyu Sang, et al.
Publicado: (2022)

Efficacy of topical cyclosporine 0.05% and osmoprotective lubricating eye drops in treating dry eye disease and inflammation
por: Mullick, Ritika, et al.
Publicado: (2021)

Re-construction layer effect of LiNi(0.8)Co(0.15)Mn(0.05)O(2) with solvent evaporation process
por: Park, Kwangjin, et al.
Publicado: (2017)

Improved Electrochemical Performance of Surface Coated LiNi(0.80)Co(0.15)Al(0.05)O(2) With Polypyrrole
por: Chen, Zhaoyong, et al.
Publicado: (2019)

Cyclosporine a 0.05% eye drops for the treatment of subepithelial infiltrates after epidemic keratoconjunctivitis
por: Okumus, Seydi, et al.
Publicado: (2012)

Preclinical Efficacy Comparison of Cyclosporine Ophthalmic Solution 0.09% vs Cyclosporine Ophthalmic Emulsion 0.05% vs Ciclosporin Ophthalmic Emulsion 0.1% in a NOD Mouse Model of Dry Eye Disease
por: Burade, Vinod, et al.
Publicado: (2020)

Retrospective Review on the Use of Topical Cyclosporin A 0.05% for Paediatric Allergic Conjunctivitis in Hong Kong Chinese
por: Wu, Macy M. S., et al.
Publicado: (2014)

LiNi(0.8)Co(0.15)Al(0.05)O(2): Enhanced Electrochemical Performance From Reduced Cationic Disordering in Li Slab
por: Xiao, Peng, et al.
Publicado: (2017)

Cyclosporine A (0.05%) Ophthalmic Gel in the Treatment of Dry Eye Disease: A Multicenter, Randomized, Double-Masked, Phase III, COSMO Trial
por: Peng, Wenyan, et al.
Publicado: (2022)

Origin of colossal dielectric permittivity of rutile Ti(0.9)In(0.05)Nb(0.05)O(2): single crystal and polycrystalline
por: Song, Yongli, et al.
Publicado: (2016)

Efficacy of 0.05% cyclosporine A on the lipid layer and meibomian glands after cataract surgery: A randomized, double-masked study
por: Kang, Min Seung, et al.
Publicado: (2021)

PERSIST: Physician’s Evaluation of Restasis(®) Satisfaction in Second Trial of topical cyclosporine ophthalmic emulsion 0.05% for dry eye: a retrospective review
por: Mah, Francis, et al.
Publicado: (2012)

Clinical utility of cyclosporine (CsA) ophthalmic emulsion 0.05% for symptomatic relief in people with chronic dry eye: a review of the literature
por: Rhee, Michelle K, et al.
Publicado: (2017)

Mechanical Composite of LiNi(0.8)Co(0.15)Al(0.05)O(2)/Carbon Nanotubes with Enhanced Electrochemical Performance for Lithium-Ion Batteries
por: Zhang, Liping, et al.
Publicado: (2017)

Efficacy, Safety and Steroid-sparing Effect of Topical Cyclosporine A 0.05% for Vernal Keratoconjunctivitis in Indian Children
por: Chatterjee, Arkendu, et al.
Publicado: (2019)

Efficacy of 0.05% Chlorhexidine and 0.05% Cetylpyridinium Chloride Mouthwash to Eliminate Living Bacteria on In Situ Collected Biofilms: An In Vitro Study
por: Becker, Kathrin, et al.
Publicado: (2021)

Are Only p-Values Less Than 0.05 Significant? A p-Value Greater Than 0.05 Is Also Significant!
por: Kwak, Sanggyu
Publicado: (2023)

The IMPACT study: a prospective evaluation of the effects of cyclosporine ophthalmic emulsion 0.05% on ocular surface staining and visual performance in patients with dry eye
por: Stonecipher, Karl G, et al.
Publicado: (2016)

0.05 - 100 MHz 4 W amplifier
por: Paoluzzi, M
Publicado: (1997)

Halometasone monohydrate (0.05%) in occupational contact dermatitis
por: Maiti, Rituparna, et al.
Publicado: (2016)

Dataset on the electronic and thermal transport properties of quaternary compounds of (PbTe)(0.95−x)(PbSe)(x)(PbS)(0.05)
por: Ginting, Dianta, et al.
Publicado: (2017)

p < 0.05, < 0.01, < 0.001, < 0.0001, < 0.00001, < 0.000001, or < 0.0000001 …
por: Zhu, Weimo
Publicado: (2016)

Comparison of Pterygium Recurrence with and without Using Postsurgical Topical Cyclosporin A 0.05%: A Randomized Clinical Trial
por: Alizadeh, Yousef, et al.
Publicado: (2022)

A Study to Explore the Suitability of LiNi(0.8)Co(0.15)Al(0.05)O(2)/Silicon@Graphite Cells for High-Power Lithium-Ion Batteries
por: Cabello, Marta, et al.
Publicado: (2021)

Cobalt-Free Layered LiNi(0.8)Mn(0.15)Al(0.05)O(2)/Graphene Aerogel Composite Electrode for Next-Generation Li-Ion Batteries
por: Kuruahmet, Deniz, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_k3hofve2gbhibtgqprhgm90r29